3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
3
Thoracic
1
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Neoplasms
2
Prostatic Neoplasms
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Neuroblastoma
1
Meningioma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Interventions
Nivolumab
4
Magnetic Resonance Spectroscopy
4
fludarabine
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Cisplatin
3
ulixertinib
2
sargramostim
2
X-Rays
2
Trastuzumab
2
Sunitinib
2
Stem Cell Transplantation
2
Specimen Handling
2
Sirolimus
2
Oxaliplatin
2
Melphalan
2
Leucovorin
2
FAPI-46
2
Erlotinib Hydrochloride
2
Cryosurgery
2
Crizotinib
2
Capecitabine
2
Busulfan
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
sapanisertib
1
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Hematologic Tests
×
CNS
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled